Quanta Inc (fka QNTA)

[Dragon Lady]

QNTA: NEW_MedoLife Rx MERGER_Sr_Mgt TEAM_HAS_STELLAR_CREDENTIALS:

THIS IS THE GUY - that is going to get this BRAND NEW COMPANY MedoLife Rx ACROSS THE FDA IND FINISH LINE FOLKS - he's got the credentials and has ridden the FDA rodeo like a freaking super star bronco buster more times than can be counted :)

LOOK at the pedigree on their new CHIEF SCIENCE OFFICER who's going to get their product(s) and FDA IND real soon here - this is a TOP, TOP, TOP SHELF RESUME and NASDAQ WORTHY -

This stellar PhD/Med research cancer research expert didn't sign-on with this company to waste his time or reputation folks:

HARVARD MED for starters:)

https://ir.quantrx.com/company-information/management-team

QUOTE:

"Khalid Matalka, Ph.D., SI(ASCP)
Chief Scientific Officer

Professor Khalid Matalka received his BSc and MSc in Medical Technology in 1986 and 1988 from Yarmouk University, Jordan, and the University of Wisconsin-Milwaukee, USA. Then he received his Ph.D. in Pathology (Immunology and Cancer therapy) from Ohio State University, USA, in 1992.

After finishing his Ph.D., Dr. Matalka joined Harvard Medical School as a Postdoctoral fellow till 1994. He is an American Board Certified as a Specialist in Immunology (SI-ASCP) and a member at the American Society for Cancer Research since 1994.

Dr. Matalka enrolled in academia as an assistant professor in 1995, then promoted to associate and then a professor in 2004. Prof. Matalka held a dean position at two different academic institutions. Besides, Prof. Matalka was a consultant for twenty years to a JPM pharmaceutical company and a hospital diagnostic laboratory.

During those 22 years, Prof. Matalka was heavily involved in research mainly on immunomodulation, cancer research, and development of immunological assays. In 2016, he joined a pharmaceutical startup company named OncoTherapeutica, MA as a Chief Biologist.

While there, Prof. Matalka was developing new potential drugs for the treatment of prostate cancer and melanoma. In March 2020, Prof. Matalka joined Medolife Corporation as Chief Scientific Officer (CSO) and, in February 2021, became the CSO of the newly established Medolife Rx.

Prof. Matalka has 65 publications in peer-reviewed international journals, and he is an Associate Editor of two and a member of the editorial board of several international journals.

Prof. Matalka is known as an international reviewer in the fields of Cancer therapy, Immunomodulation, and Ethnopharmacology.
"

NIiiiiiice and WOW !!

FDA is going to sit-up and take this dude seriously when HE SUBMITS and SIGNS THEIR IND APPLICATIONS and CLINICAL DATA REPORTS etc !

HARVARD MED - among other top shelf name droppers and 65 PEER REVIEW journal pubs = BIG HITTER TERRITORY !!